Eylea

Evolution step-up growth trajectory upward trajectory
Pharma

How biosimilar developers are embracing next phase of US market

Although the so-called biosimilar ‘void’ could pose challenges to upcoming biosimilar availability, the opportunity it presents is also immense.
Bayer cross

Biosimilar competiton takes big bite out of Bayer's Eylea sales

May 12, 2026 10:51am
Eylea

Regeneron sees more regulatory issues, sales declines for Eylea

Apr 29, 2026 12:05pm
concept of two individuals in a dispute

Bayer found to have discredited industry after Roche row

Mar 13, 2026 11:45am
Bayer

Bayer's pharma division sees one more year of declining sales

Mar 4, 2026 11:35am
eyeball

Ocular's ophthalmologic version of Inlyta bests Eylea in ph. 3

Feb 17, 2026 12:15pm